Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)
This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).
The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.
MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.
The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.
Moreover, the study will assess the safety of TBE vaccination.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Cornelia Staehelin, PD. Dr. med.
- 电话号码:+41 31 632 01 83
- 邮箱:cornelia.staehelin@insel.ch
研究联系人备份
- 姓名:Robert Hoepner, Prof. Dr. med.
- 电话号码:+41 316325835
- 邮箱:robert.hoepner@insel.ch
学习地点
-
-
-
Bern、瑞士、3010
- 招聘中
- University Hospital of Bern
-
接触:
- Cornelia Staehelin, PD Dr. med
- 电话号码:+41 31 632 01 83
- 邮箱:cornelia.staehelin@insel.ch
-
接触:
- Robert Hoepner, PD Dr. med.
- 电话号码:+41 +41 632 60 93
- 邮箱:robert.hoepner@insel.ch
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.
In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).
描述
Inclusion Criteria
-
Adult (≥ 18 years old)
-
Suspected neuroimmunological disorder with CNS affection
- including suspicion of Multiple Sclerosis (MS)
- Diagnosed Multiple Sclerosis (MS)
- Clinically Isolated Syndrome
- Radiologically Isolated Syndrome
-
stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion
-
treated with non-B-cell depleting therapies for at least 6 months in monotherapy
-
TBE vaccine:
- never been vaccinated against TBE or
- clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
-
Provided written informed consent
Exclusion Criteria
- Any B-cell depleting therapies in last 12 months prior to recruitment
- Any other vaccination in last 2 months prior to recruitment
- Any foreseeable and necessary other vaccination up to 42 days post dose 1
- Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Primary vaccination series or Booser against TBE in patients with MS
According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary immunogenicity endpoint
大体时间:42 days post dose 1
|
Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA |
42 days post dose 1
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Immunogenicity endpoint
大体时间:42 days post dose 1
|
Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1) |
42 days post dose 1
|
|
Immunogenicity endpoint
大体时间:7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
大体时间:7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
大体时间:at each time point (7 months)
|
Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA. |
at each time point (7 months)
|
|
Immunogenicity endpoint
大体时间:at each time point (7 months)
|
Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT. |
at each time point (7 months)
|
|
Safety endpoint
大体时间:42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection. |
42 (+/-7d) post dose 1
|
|
Safety endpoint
大体时间:42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
大体时间:42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Neurological assessment (EDSS) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
大体时间:42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
大体时间:42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions) |
42 (+/-7d) post dose 1
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2025-01767
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.